Cantel Medical Corp. (NYSE:CMD) EVP Eric W. Nodiff sold 2,868 shares of the stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $97.55, for a total transaction of $279,773.40. Following the completion of the transaction, the executive vice president now directly owns 39,102 shares of the company’s stock, valued at approximately $3,814,400.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cantel Medical Corp. (NYSE CMD) opened at 96.38 on Wednesday. The company has a market cap of $4.00 billion, a PE ratio of 56.36 and a beta of 1.25. The stock has a 50 day moving average of $90.73 and a 200-day moving average of $79.48. Cantel Medical Corp. has a 12-month low of $68.19 and a 12-month high of $99.83.
Cantel Medical Corp. (NYSE:CMD) last issued its quarterly earnings data on Thursday, September 28th. The company reported $0.54 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.02. Cantel Medical Corp. had a return on equity of 17.60% and a net margin of 9.27%. The company had revenue of $205.50 million during the quarter, compared to analyst estimates of $200.32 million. The business’s revenue was up 14.8% compared to the same quarter last year. On average, equities research analysts anticipate that Cantel Medical Corp. will post $2.37 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/2982097/eric-w-nodiff-sells-2868-shares-of-cantel-medical-corp-cmd-stock.html.
A number of research analysts have recently commented on CMD shares. Zacks Investment Research raised shares of Cantel Medical Corp. from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical Corp. in a report on Friday, September 1st. Finally, Sidoti raised shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 target price for the company in a report on Wednesday, August 2nd. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $91.67.
Several hedge funds and other institutional investors have recently modified their holdings of the company. First Trust Advisors LP grew its holdings in shares of Cantel Medical Corp. by 6.8% during the third quarter. First Trust Advisors LP now owns 11,677 shares of the company’s stock worth $1,100,000 after purchasing an additional 739 shares in the last quarter. Globeflex Capital L P purchased a new stake in Cantel Medical Corp. in the second quarter worth approximately $114,000. Integrated Investment Consultants LLC purchased a new stake in Cantel Medical Corp. in the second quarter worth approximately $161,000. LS Investment Advisors LLC purchased a new stake in Cantel Medical Corp. in the second quarter worth approximately $172,000. Finally, Ingalls & Snyder LLC purchased a new stake in Cantel Medical Corp. in the third quarter worth approximately $235,000. 83.82% of the stock is owned by institutional investors.
Cantel Medical Corp. Company Profile
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.